Horizon Therapeutics PLC (HZNP)
| Market Cap | 14.90B |
| Revenue (ttm) | 3.81B |
| Net Income (ttm) | 764.96M |
| Shares Out | 230.38M |
| EPS (ttm) | 3.20 |
| PE Ratio | 20.21 |
| Forward PE | 13.95 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,289,898 |
| Open | 64.97 |
| Previous Close | 64.90 |
| Day's Range | 63.86 - 65.14 |
| 52-Week Range | 60.76 - 120.54 |
| Beta | 1.11 |
| Analysts | Buy |
| Price Target | 140.25 (+116.8%) |
| Earnings Date | Aug 3, 2022 |
About HZNP
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI ... [Read more...]
Financial Performance
In 2021, HZNP's revenue was $3.23 billion, an increase of 46.63% compared to the previous year's $2.20 billion. Earnings were $534.49 million, an increase of 37.12%.
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for HZNP stock is "Buy." The 12-month stock price forecast is 140.25, which is an increase of 116.84% from the latest price.
News
New Contender Viridian Takes Aim At Horizon's Eye Drug, And Rockets
Viridian unveiled promising results Monday for its Horizon-rivaling thyroid eye disease treatment — and the biotech stocks diverged. The post New Contender Viridian Takes Aim At Horizon's Eye Drug, And ...
Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases
WALTHAM, Mass. and DUBLIN , Aug. 15, 2022 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Na...
Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases
WALTHAM, Mass. & DUBLIN--(BUSINESS WIRE)--Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), tod...
Horizon (HZNP) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
Horizon's (HZNP) earnings and revenues lag estimates in the second quarter of 2022. The company lowers full-year revenue guidance for 2022.
Horizon Therapeutics (HZNP) Q2 Earnings and Revenues Lag Estimates
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of -20.74% and 6.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Horizon Therapeutics plc Reports Second-Quarter 2022 Financial Results and Revises Full-Year 2022 Net Sales and Adjus...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc Reports Second-Quarter 2022 Financial Results and Revises Full-Year 2022 Net Sales and Adjusted EBITDA Guidance
Why Horizon Therapeutics (HZNP) Might Surprise This Earnings Season
Horizon Therapeutics (HZNP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Horizon Therapeutics (HZNP) Keep the Earnings Surprise Streak Alive?
Horizon Therapeutics (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Analysts Estimate Horizon Therapeutics (HZNP) to Report a Decline in Earnings: What to Look Out for
Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Horizon Therapeutics plc Named a Best Company for Multicultural Women
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named by Seramount (formerly Working Mother media) to its Best Companies for Multicultural Women list. T...
Horizon Therapeutics plc Announces Inaugural #RAREis Global Advocate Grant Recipients
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the 30 patient advocacy organizations selected to receive the inaugural #RAREis Global Advocate Grant, which awards each ...
Horizon (HZNP) Gets FDA Nod for Krystexxa's Label Expansion
The FDA approves Horizon's (HZNP) sBLA for Krystexxa injection plus methotrexate to help people suffering from uncontrolled gout achieve a complete response to therapy.
Horizon Therapeutics plc Announces Wanda Durant Has Joined Olympian Gail Devers to Raise Awareness of Thyroid Eye Dis...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics Partners with Wanda Durant and Gail Devers to Raise Awareness of Thyroid Eye Disease Among Graves' Disease Community
FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help Mor...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) expan...
Horizon Therapeutics plc to Release Second-Quarter 2022 Financial Results and Host Webcast on Aug. 3, 2022
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its second-quarter 2022 financial results on Wednesday, Aug. 3, 2022. Following the announcement, Ho...
New Analysis Finds UPLIZNA® (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Di...
DUBLIN--(BUSINESS WIRE)--New analysis finds UPLIZNA (inebilizumab) effective among European populations with neuromyelitis optica spectrum disorder (NMOSD).
Horizon Therapeutics plc Submits Regulatory Filing for UPLIZNA® (inebilizumab) in Brazil
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics has submitted a regulatory filing for UPLIZNA® in Brazil for NMOSD.
Horizon Therapeutics plc Named One of the Fortune Best Workplaces in Chicago™
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to the Fortune Best Workplaces in Chicago 2022 list, ranking No. 3 in the large company category. ...
Analysis of Pooled Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials Reinforces Safety Profile in People with Th...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced results of a new analysis examining rates of hyperglycemia among patients treated with TEPEZZA for TED compared to placeb...
Horizon Therapeutics plc Named a Top Company for Executive Women
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been recognized by Seramount (formerly Working Mother media) as a Top 75 Company for Executive Women. Seramou...
Horizon Therapeutics plc to Present at the Goldman Sachs 43rd Annual Global Health Care Conference
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in June: Goldman Sachs 43rd Annual Global Health Care Confe...
Horizon Therapeutics plc to Highlight Data and Education on Thyroid Eye Disease (TED) at the Endocrine Society (ENDO)...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announces data and education on Thyroid Eye Disease (TED) to be presented at the Endocrine Society Annual Conference, ENDO 2022.
Data Presented from the MIRROR Randomized Controlled Trial Demonstrate KRYSTEXXA® (pegloticase injection) Plus Methot...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new KRYSTEXXA® (pegloticase injection) datasets on the primary endpoint results from the MIRROR rando...
Horizon Therapeutics plc Wins 2022 International CSR Excellence Award for #RAREis Adoption Fund
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the company has won an International Corporate Social Responsibility (CSR) Excellence Award for its partnership with Gift...
Analysis from the Phase 3 N-MOmentum Study Demonstrates the Effectiveness of UPLIZNA® (inebilizumab-cdon) Among Neuro...
DUBLIN--(BUSINESS WIRE)--Analysis from the Phase 3 N-MOmentum study demonstrates the effectiveness of UPLIZNA among NMOSD patients with genetic variations.